Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Current Investments: 2016-2025

Historic Cash & Current Investments for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $127.0 million.

  • UroGen Pharma's Cash & Current Investments fell 49.10% to $127.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $716.6 million, marking a year-over-year decrease of 9.49%. This contributed to the annual value of $236.7 million for FY2024, which is 72.80% up from last year.
  • UroGen Pharma's Cash & Current Investments amounted to $127.0 million in Q3 2025, which was down 19.06% from $157.0 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Cash & Current Investments high stood at $249.6 million for Q3 2024, and its period low was $47.3 million during Q2 2023.
  • Its 3-year average for Cash & Current Investments is $160.7 million, with a median of $157.0 million in 2025.
  • In the last 5 years, UroGen Pharma's Cash & Current Investments tumbled by 52.32% in 2023 and then spiked by 409.67% in 2024.
  • Quarterly analysis of 5 years shows UroGen Pharma's Cash & Current Investments stood at $89.1 million in 2021, then climbed by 12.14% to $100.0 million in 2022, then skyrocketed by 37.02% to $137.0 million in 2023, then surged by 72.80% to $236.7 million in 2024, then plummeted by 49.10% to $127.0 million in 2025.
  • Its last three reported values are $127.0 million in Q3 2025, $157.0 million for Q2 2025, and $195.9 million during Q1 2025.